Re-Treatment of Relapsed Indolent B-Cell Lymphoma With Rituximab-Reference-Cited by-同舟云学术

Re-Treatment of Relapsed Indolent B-Cell Lymphoma With Rituximab

Published:2001-02 Issue:2 Volume:73 Page:213-221
ISSN:0925-5710
Container-title:International Journal of Hematology
language:en
Short-container-title:Int J Hematol

Author:

Igarashi Tadahiko, ,Ohtsu Tomoko,Fujii Hirofumi,Sasaki Yasutsuna,Morishima Yasuo,Ogura Michinori,Kagami Yoshitoyo,Kinoshita Tomohiro,Kasai Masaharu,Kiyama Yoshio,Kobayashi Yukio,Tobinai Kensei

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Link

http://link.springer.com/article/10.1007/BF02981940/fulltext.html

Reference27 articles.

1. Reff ME, Carner K, Chambers KS, et al. Depletion of B-cells in vivo by a chimeric mouse human monoclonal antibody to CD20.Blood. 1994;83:435–445.

2. Maloney DG, Liles TM, Czerwinski DK, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma.Blood. 1994;84:2457–2466.

3. Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma.Blood. 1997;90:2188–2195.

4. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.J Clin Oncol. 1998;16:2825–2833.

5. Tobinai K, Kobayashi Y, Narabayashi M, et al. Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma.Ann Oncol. 1998;9:527–534.

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapy in indolent Non-Hodgkin's Lymphoma;Leukemia Research Reports;2022

2. Analysis of Japanese patients from the AUGMENT phase III study of lenalidomide + rituximab (R2) vs. rituximab + placebo in relapsed/refractory indolent non-Hodgkin lymphoma;International Journal of Hematology;2019-12-19

3. Resistance to Monoclonal Antibody Therapeutics in Lymphoma;Resistance to Targeted Anti-Cancer Therapeutics;2019

4. Rituximab (Rituxan®);Handbook of Therapeutic Antibodies;2014-08-12

5. Phase 1/2 Study of Ocaratuzumab, an Fc-Engineered Humanized Anti-CD20 Monoclonal Antibody, in Low-Affinity FcγRIIIa Patients with Previously Treated Follicular Lymphoma;Leukemia & Lymphoma;2014-07-14